Needham & Company LLC restated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research note published on Tuesday, Benzinga reports. Needham & Company LLC currently has a $45.00 price objective on the biotechnology company’s stock. Several other analysts also recently commented on the stock. EF Hutton Acquisition Co. I restated […]
Shares of Merus (NASDAQ:MRUS – Get Rating) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price […]
Shares of Merus (NASDAQ:MRUS – Get Rating) have been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price […]
Merus (NASDAQ:MRUS – Get Rating) had its target price upped by HC Wainwright from $40.00 to $48.00 in a report issued on Friday, The Fly reports. A number of other analysts also recently commented on the stock. BMO Capital Markets increased their price objective on shares of Merus from $47.00 to $49.00 in a report […]
Merus (NASDAQ:MRUS – Get Rating) had its target price raised by Citigroup from $38.00 to $47.00 in a research note published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Other analysts also recently issued reports about the stock. Needham & Company LLC reiterated a buy […]